INNOVATING
Zambon teamed up last year with a product
development company called Newron. This
Italian public trade company, focused on the
central nervous system, has a specific product
for Parkinson’s disease, Safinamida, which
starting next year will include Zambon in a new
therapeutic area. “We will market the product
everywhere except Asia. We also have some
molecules being developed by us in partnership
with other companies, which are the main
products for the treatment of asthma and
chronic obstructive pulmonary disease. We now
have two products still being developed, which
are in phase two for these therapies,” says
Borges.
The company is also implementing a
project using the iPad for propagandists as a
productivity tool. “We started using the tablet
as a pilot this month. From October, everyone
Medications
page 487
September 2012
